News
EQS-Adhoc: MAQUET Medical Systems AG submitted specified squeeze-out request and has determined cash compensation for minority shareholders of Pulsion Medical Systems SE to be EUR 20.57
EQS-News: BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application
Humana Announces New Agreements to Expand Specialized Care Programs for Patients Living with Musculoskeletal Conditions
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced new strategic, individual value-based care partnerships with Vori Health and HOPCo, in addition to the company’s
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
EQS-News: FamiCord AG significantly increases revenue and earnings in the first half of 2025 and shifts focus even more strongly to core business in the future
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:
-
The 2025 Wells Fargo Healthcare Conference on
Humana Earns 2025 Great Place to Work Certification™ and PEOPLE Companies That Care® Recognition
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, has been named a Certified™ Great Place To Work® for the fourth consecutive year and has earned a place on
EQS-News: Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
EQS-Adhoc: MeVis Medical Solutions AG: Forecast adjustment for the 2024/2025 fiscal year
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised
Sonova expands Infinio range and enters new market segment with Phonak’s smallest and first rechargeable in-the-ear hearing aid
EQS-News: Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: MEDICLIN reports positive interim results for the first half of 2025
Sensorion Announces Its Participation In Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights:
-
Revenue grew 15% year-over-year to
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
EQS-News: Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101